Innova Captab

What Innova Captab does

Innova Captab Limited is an integrated Indian pharmaceutical company operating across the full pharmaceutical value chain through three business segments: CDMO services and products, domestic branded generics, and international branded generics. Incorporated in 2005 and listed on NSE/BSE on December 29, 2023, the company runs five manufacturing facilities with nine independent blocks (located in Baddi, Kathua and elsewhere) producing tablets, capsules, dry syrups, dry powder injections, ointments, liquid orals, and complex modified/sustained release dosage forms. The company claims the position of the 2nd largest domestic formulations CDMO in India, serving marquee customers that include Lupin, Mankind, Glenmark, Wockhardt, Intas, Emcure, JB Chemicals, Ajanta, Indoco, Eris and others. As of FY2026 it reported consolidated sales of Rs 1,630.02 crore (+31.06% YoY) and net profit of Rs 140.92 crore.

The underlying technology stack is conventional pharmaceutical manufacturing rather than a software or AI platform. It comprises WHO-GMP and EU-GMP certified facilities, a DSIR-recognized R&D laboratory for formulation and analytical method development, and a quality control laboratory equipped with HPLC, gas chromatography, FTIR and spectrophotometers. Regulatory breadth is a meaningful technology differentiator: the company holds EU-GMP (Baddi Unit 2, Block C, approved 2024), UK MHRA inspection clearance, ISO 9001:2015, and registrations across East Africa (Ethiopia FMHACA, Tanzania TMDA, Uganda NDA) and South Asia (Sri Lanka MTPS). The portfolio includes 2,400+ CDMO products and 200+ internationally registered products, with 36 fresh registration applications in process.

The business model combines B2B contract manufacturing with branded generics distribution. CDMO revenue is generated through direct B2B sales to pharmaceutical companies for contract development and manufacturing. Domestic branded generics revenue flows through approximately 5,000 distributors and stockists reaching 150,000+ retail pharmacies across India, supplemented by e-commerce pharmacy channels. International branded generics revenue is generated through direct exports to 17 countries across emerging, semi-regulated and regulated markets. Pricing is not publicly disclosed and is quote-based for CDMO services and distributor-priced for generics. Forward, the company is investing in a greenfield plant in Kathua (J&K) and a new R&D center in Panchkula (Haryana) to support capacity expansion and pipeline development.

Name

Innova Captab

Legal name

Innova Captab Limited

Website

https://innovacaptab.com

Company type

Public

Founded year

2005

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Innova Captab is an integrated Indian pharmaceutical company operating five manufacturing facilities across CDMO services, domestic branded generics, and international branded generics, serving marquee pharma companies and distributing through 150,000+ retail pharmacies across 17 countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing and Generic Formulations

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

Keywords

• Pharmaceutical contract manufacturing
• Generic formulation development
• CDMO services
• Branded generic medicines
• Pharmaceutical drug exports

Headquarters

HQ city

Haryana

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. CDMO Services and Products: Contract development and manufacturing services providing research, product development and manufacturing for pharmaceutical companies, supporting their domestic sales and exports to certain markets
2. Domestic Branded Generics: Development, manufacture and distribution of generic formulation products marketed under own brand names in India through distributors, stockists and retailers
3. International Branded Generics: Export of branded generic products to emerging and semi-regulated international markets with expansion to regulated markets like UK and Canada

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Innova Captab is an integrated pharmaceutical company engaged in contract development and manufacturing organization (CDMO) services along with the manufacturing, distribution, and marketing of branded generic formulations. It produces generic medicines across multiple dosage forms including tablets, capsules, dry syrups, dry powder injections, ointments, and liquid orals, supplying both domestic Indian pharmaceutical companies as a CDMO partner and selling branded generics through pan-Indian distribution and international exports.

Product overview

Innova Captab is an integrated pharmaceutical company operating across the entire pharmaceutical value chain. The company offers three core business segments: (1) CDMO Services and Products providing contract development and manufacturing to pharmaceutical companies; (2) Domestic Branded Generics for the Indian market through a network of distributors, stockists and pharmacies; and (3) International Branded Generics serving emerging markets and regulated markets like UK and Canada. The company manufactures formulations including tablets, capsules, dry syrups, dry powder injections, ointments, and liquid orals across multiple therapeutic areas. The company operates five manufacturing facilities with nine independent manufacturing blocks.

Differentiator

Problem solved

Functional benefit

Products and services

• CDMO Services and Products Contract development and manufacturing organization services providing research, product development, and formulation manufacturing to pharmaceutical companies. Capabilities span oral solids, oral liquids, dry syrups, injectables, dry powder injections, ointments, liquid orals, and complex delivery forms including modified and sustained release forms and tablets in capsules.
• Domestic Branded Generics Development, manufacture, and distribution of generic formulation products marketed in India under Innova Captab's own brand names. Portfolio includes tablets, capsules, dry syrups, dry powder injections, ointments, and liquid orals across cardiovascular, antidiabetic, anti-infective, CNS, and gastrointestinal therapeutic areas.
• International Branded Generics Export of branded generic products to emerging and semi-regulated international markets, with expansion into regulated markets including the United Kingdom and Canada through technology transfer and product registration routes. Supported by 200 active product registrations with international authorities and 36 fresh registrations in process.

Quantifiable outcome

• Revenue grew 31.06% YoY to Rs 1,630.02 crore in FY2026
• +3 more outcomes

Named customers17 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Sharon Bio-Medicine LimitedcoreStrategic or Co-development Partner · 2 August 2023Acquired Sharon Bio-Medicine Limited, a pharmaceutical company involved in developing, manufacturing, and commercializing pharmaceutical products. Sharon Bio-Medicine operates across three segments: Active Pharma Ingredients, Formulations, and Toxicology.
• Univentis Medicare LimitedcoreStrategic or Co-development PartnerIncorporated in 2015 for strengthening the Company's marketing operations and market presence in domestic branded generics business.

Scale indicators14 records

Recent moves13 records

Expansion highlights5 records

Direct peers

• Laurus Labs: Indian pharma company combining API manufacturing with CDMO and generics businesses. Comparable as an integrated Indian pharma manufacturer with similar customer profile of large generic pharmaceutical companies and comparable regulatory certifications.
• Syngene International: Indian listed contract research and manufacturing organization (CRO/CDMO) serving global pharma companies with formulation and API development capabilities. Highly comparable as a domestic Indian CDMO with similar end markets and customer base, though more research-oriented.
• Granules India: Indian pharmaceutical manufacturer focused on active pharmaceutical ingredients, pharmaceutical formulation intermediates, and finished dosages with significant CDMO operations. Comparable business model with API+formulations integration and similar international expansion profile.
• NATCO Pharma: Indian pharmaceutical company focused on generic formulations and API manufacturing with oncology and complex generics focus. Comparable as a mid-sized Indian pharma with formulations manufacturing and similar regulatory approach.
• Strides Pharma Science: Indian pharmaceutical company focused on generic formulations with manufacturing services across multiple dosage forms and regulated market presence. Comparable as an Indian generics manufacturer with international expansion and similar customer overlap.
• Morepen Laboratories: Indian pharmaceutical manufacturer with API (loratadine), formulations, and branded generics business. Comparable as a mid-sized Indian pharma with similar product portfolio focus, regulatory certifications, and domestic distribution.
• Jubilant Pharmova: Indian pharmaceutical company with CDMO, generics, and specialty pharma segments including radiopharma. Comparable as a diversified Indian pharma with contract manufacturing services and similar regulatory positioning for global markets.
• Divi's Laboratories: Leading Indian API and intermediates manufacturer with growing formulations CDMO business. Comparable as a vertically integrated Indian pharma manufacturer serving global and domestic pharma customers with similar regulatory profile (USFDA, EU-GMP).

Broad incumbents

• Piramal Pharma: Diversified Indian pharmaceutical company with significant CDMO operations (Piramal Pharma Solutions) serving global customers. Comparable CDMO business model though at much larger scale and with broader global footprint.
• Aurobindo Pharma: One of India's largest generic pharmaceutical manufacturers with substantial in-house API and formulation manufacturing. Comparable as an Indian formulations giant with overlapping customer segments and export market exposure, though much larger scale and broader portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=-qUHXv1iZ1A
• LinkedInlinkedin.com/company/innova-captab

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innova Captab